These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

976 related items for PubMed ID: 11136569

  • 1. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 2. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 3. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.
    Cancer Res; 1993 Jun 01; 53(11):2513-21. PubMed ID: 8388317
    [Abstract] [Full Text] [Related]

  • 4. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 5. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E, Pollow K, Hasenclever D, Schormann W, Hermes M, Schmidt M, Puhl A, Brulport M, Bauer A, Petry IB, Koelbl H, Hengstler JG.
    Gynecol Oncol; 2008 Mar 01; 108(3):569-76. PubMed ID: 18222533
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, Dano K, Klijn JG, Brünner N, Foekens JA.
    Clin Cancer Res; 1995 Oct 01; 1(10):1079-87. PubMed ID: 9815897
    [Abstract] [Full Text] [Related]

  • 7. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 01; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 8. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.
    Cancer Res; 2004 Jul 01; 64(13):4563-8. PubMed ID: 15231667
    [Abstract] [Full Text] [Related]

  • 9. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 01; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 10. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ, Rha SY, Chung HC, Yoo NC, Roh JK, Yang WI, Lee KS, Min JS, Kim BS, Chung HC.
    Int J Mol Med; 2000 Sep 01; 6(3):301-5. PubMed ID: 10934293
    [Abstract] [Full Text] [Related]

  • 11. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T, Yabe H, Morioka H, Yamada R, Nakagawa T, Toyama Y.
    Anticancer Res; 2000 Sep 01; 20(5A):3031-6. PubMed ID: 11062719
    [Abstract] [Full Text] [Related]

  • 12. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C, Moses EK, Quinn MA, Rice GE.
    Gynecol Oncol; 2000 Nov 01; 79(2):244-50. PubMed ID: 11063652
    [Abstract] [Full Text] [Related]

  • 13. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS.
    Cancer; 1997 Mar 01; 79(5):878-83. PubMed ID: 9041148
    [Abstract] [Full Text] [Related]

  • 14. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.
    Cancer; 2004 Aug 01; 101(3):486-94. PubMed ID: 15274061
    [Abstract] [Full Text] [Related]

  • 15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 01; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H, Brünner N, Francis D, Osterlind K, Rønne E, Hansen HH, Danø K, Grøndahl-Hansen J.
    Cancer Res; 1994 Sep 01; 54(17):4671-5. PubMed ID: 8062262
    [Abstract] [Full Text] [Related]

  • 17. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
    Taponeco F, Curcio C, Giuntini A, Nardini V, Fornaciari G, Artini PG, D'Ambrogio G, Genazzani AR.
    J Exp Clin Cancer Res; 2001 Jun 01; 20(2):239-46. PubMed ID: 11484981
    [Abstract] [Full Text] [Related]

  • 18. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR.
    Cancer Res; 1994 Jun 01; 54(11):2900-7. PubMed ID: 8187075
    [Abstract] [Full Text] [Related]

  • 19. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ, Duggan C.
    Clin Biochem; 2004 Jul 01; 37(7):541-8. PubMed ID: 15234235
    [Abstract] [Full Text] [Related]

  • 20. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot AJ, van Tienoven DT, Beex LV, Sweep FC.
    Thromb Haemost; 2004 Mar 01; 91(3):514-21. PubMed ID: 14983227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.